Abstract Number: 0432 • ACR Convergence 2021
Anti-IL5 Therapy in Eosinophilic Granulomatosis with Polyangiitis (EGPA): A Longitudinal Follow-up Study ≥ 24months
Background/Purpose: In the randomized, placebo-controlled MIRRA trial for relapsing and refractory eosinophilic granulomatosis with polyangiitis (EGPA), adjuvant therapy with 300mg anti-IL5 mAB Mepolizumab [MEPO] for…Abstract Number: 1405 • ACR Convergence 2021
Effectiveness of Tocilizumab in Cranial and Extracranial Phenotypes of Giant Cell Arteritis: Multicenter Study of 471 Cases
Background/Purpose: Giant cell arteritis (GCA) may be divided into cranial, and extracranial GCA phenotypes. Tocilizumab (TCZ) has shown efficacy and safety in GCA.Our aim was…Abstract Number: 1865 • ACR Convergence 2021
Incidence, Prevalence, and Mortality of Chronic Periaortitis: A Population-based Study
Background/Purpose: Chronic periaortitis is an inflammatory condition that typically involves the infrarenal portion of the abdominal aorta. To date, no epidemiologic studies have been performed…Abstract Number: 0502 • ACR Convergence 2021
Global Transcriptomic Profiling Identifies Differential Gene Expression Signatures Between Inflammatory and Non-inflammatory Aortic Aneurysms
Background/Purpose: Non-infectious aortitis may be a manifestation of systemic large vessel vasculitis such as giant cell arteritis (GCA) or may be a form of single…Abstract Number: 1406 • ACR Convergence 2021
Incidence and General Clinical Features of Giant Cell Arteritis in the ARTESER Multicenter Study
Background/Purpose: Epidemiological information on Giant Cell Arteritis (GCA) comes mainly from the Scandinavian countries of northern Europe, which show a higher incidence than the countries…Abstract Number: 1866 • ACR Convergence 2021
Vasculitis in Patients with Sarcoidosis: A Single-Institution Case Series of 17 Patients
Background/Purpose: Vasculitis in patients with sarcoidosis is rare and can affect blood vessels of any size. Limited information describing this association is available. The purpose…Abstract Number: 0504 • ACR Convergence 2021
Longitudinal Patterns of Vascular Inflammation in Large-vessel Vasculitis
Background/Purpose: The two main forms of large vessel vasculitis (LVV), giant cell arteritis (GCA) and Takayasu’s arteritis (TAK), are clinically heterogenous diseases with variable disease…Abstract Number: 1408 • ACR Convergence 2021
Treatment of Giant Cell Arteritis in the ARTESER Multicenter Study of 1675 Patients
Background/Purpose: Glucocorticoids (GC) are the mainstay therapy in Giant Cell Arteritis (GCA), initially at high doses (40-60 mg/day) followed by gradual glucocorticoid tapering. This treatment,…Abstract Number: 1867 • ACR Convergence 2021
Investigating Adenosine Deaminase 2 Activity in Large Vessel Vasculitis
Background/Purpose: Deficiency of adenosine deaminase 2 (DADA2) leads to a broad phenotype that in some resembles polyarteritis nodosa with fever and rash, but in others…Abstract Number: 0525 • ACR Convergence 2021
STEAP3, FZD2 and EGFLAM Are Novel Genetic Risk Loci for Granulomatosis with Polyangitis: A Genome Wide Association Study from UK Biobank
Background/Purpose: Granulomatosis with Polyangitis (GPA) is a systemic ANCA associated small vessel vasculitis. Prior genetic studies demonstrated a strong association of HLA Class II region…Abstract Number: 1409 • ACR Convergence 2021
Clinical Features at Disease Onset of Different Subsets of Large-vessel-giant Cell Arteritis in a Monocentric Cohort of 100 Patients
Background/Purpose: Giant Cell Arteritis (GCA) is the most frequent systemic vasculitis in patients older than 50 years involving medium-sized and large arteries. Inflammation of the…Abstract Number: 1872 • ACR Convergence 2021
Differentiating Primary Central Nervous System Vasculitis from Non-inflammatory Intracranial Vasculopathy
Background/Purpose: Establishing the diagnosis of Primary central nervous system vasculitis CNSV is challenging. In this study we aimed to investigate distinguishing primary CNSV compared to…Abstract Number: 0622 • ACR Convergence 2021
Ethnic Disparities in Giant-Cell Arteritis: A Clinical Comparison Among Caucasian and Hispanic Patients in the Inland Empire of Southern California
Background/Purpose: Giant-Cell Arteritis (GCA) is the most common systemic vasculitis among North Americans, historically described in Caucasian populations, with limited clinical data in other ethnic…Abstract Number: 1410 • ACR Convergence 2021
Predictors of Relapse in Giant-Cell Arteritis: A Retrospective Single Center Analysis
Background/Purpose: Giant Cell Arteritis (GCA) is the most common systemic vasculitis in North America, typically affecting Caucasian female adults over 50 years of age. Flares…Abstract Number: 1874 • ACR Convergence 2021
Using 18F-fluorodeoxyglucose Positron Emission Tomography to Standardize Clinical Trial Recruitment in Takayasu’s Arteritis
Background/Purpose: Disease activity assessment can be challenging in Takayasu’s arteritis (TAK), which can lead to difficulty in determining eligibility for enrollment into randomized clinical trials…
- « Previous Page
- 1
- …
- 22
- 23
- 24
- 25
- 26
- …
- 35
- Next Page »